Webinar | From the beta-amyloid hypothesis to AI-driven discoveries of novel biomarkers and breakthrough drugs in Alzheimer’s Disease

Alzheimer’s disease research has taken center stage in the world of drug discovery and clinical development. The convergence of causal AI, supercomputing power, and multi-omic human data is allowing us to begin to unravel the molecular circuity of this debilitating disease in order to discover the next generation of breakthrough drugs and predictive biomarkers. In […]

AI-Driven Discovery of Novel Predictors of Parkinson’s Disease Progression by GNS Healthcare Appears in The Lancet Neurology

Discovery May Accelerate the Development of New Drugs & Better Match New Drugs to Individual Patients CAMBRIDGE, Mass.– Sept 26, 2017 – GNS Healthcare (GNS), a leading precision medicine company, announced today the discovery of genetic and molecular markers of faster motor progression of Parkinson’s Disease (PD) patients, the LINGO2 gene together with a second genetic […]